Tavakolian Shaian, Goudarzi Hossein, Torfi Farhad, Faghihloo Ebrahim
Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.
Surgical Ward, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran.
Biomed Rep. 2020 Jan;12(1):30-34. doi: 10.3892/br.2019.1257. Epub 2019 Nov 21.
Given the global outbreak of breast cancer and its debilitating effect on women's health, it is not surprising that tremendous efforts have been made with an aim of shedding more light on the mechanisms involved in the pathogenesis of this type of cancer. Among the long list of risk factors associated with this malignancy, recently, the role of microRNAs (miRNAs or miRs) has turned into a hotspot for breast cancer investigations. miRNAs approximately 20 nucleotides in length and are located in either an exon or an intron, playing a role in the regulation of gene expression. In the present study, we extracted RNA from both the serum and cancerous tissue of breast cancer patients and after synthesizing the cDNA, we performed quantitative PCR to determine the expression levels of miR-9 and miR-192. The resulting data revealed that while the mRNA expression level of miR-9 was significantly decreased in the breast cancer tissues, there was no noticeable change in the expression level of this miRNA in the serum samples. Likewise, we found that the marked downregulation of miR-192 was only restricted to the cancerous tissues, but was not found in the serum of patients. Based on the meaningful downregulation of the expression of miR-9 and miR-192, this study provides a plausible framework for these miRNAs as effective biomarkers for breast cancer patients.
鉴于全球乳腺癌的爆发及其对女性健康的严重影响，人们为更深入了解这种癌症发病机制所涉及的机制付出巨大努力也就不足为奇了。在与这种恶性肿瘤相关的众多风险因素中，最近，微小RNA（miRNA或miR）的作用已成为乳腺癌研究的热点。miRNA长度约为20个核苷酸，位于外显子或内含子中，在基因表达调控中发挥作用。在本研究中，我们从乳腺癌患者的血清和癌组织中提取RNA，合成cDNA后，进行定量PCR以确定miR-9和miR-192的表达水平。所得数据显示，虽然miR-9的mRNA表达水平在乳腺癌组织中显著降低，但该miRNA在血清样本中的表达水平没有明显变化。同样，我们发现miR-192的显著下调仅局限于癌组织，而在患者血清中未发现。基于miR-9和miR-192表达的显著下调，本研究为这些miRNA作为乳腺癌患者的有效生物标志物提供了一个合理的框架。
